This is very bullish in the sense that the story will attract new investors to a less than loved stock. As Business Week Inside Wallstreet columns go, this is extremely bullish with hardly a doubt of skepticism.
It will no doubt lead to a higher price in the short term, but may fade soon after the paper magazine is published. We will have to let the numbers and fundamentals speak for themselves over the next 6-12 mos.
So, as far as the 'pop' goes, here is my educated guess based on looking back at similar biotech stocks that have been featured recently in BW (see below) My best guess is that we see a high of $4.15 over the next week (up 24% from today's close) With any luck, the $4's will stick and we will move up into the $5's by year end with a decent biotech mkt.
ACUS shot up initially, but then dropped back to levels below where the article came into play.
My thinking is that it looked like a good short candidate given that they will likely need to issue debt or PIPE once they run out of cash in 2007. SUPG on the other hand will be profitable by mid-2007.